Healthcare Industry News: Relaxin
News Release - April 18, 2007
HealthSonix to Start Selling AquaSonix Therapy(TM) Medical Devices to Hospitals and Rehabilitation Clinics
IRVINE, CA--(Healthcare Sales & Marketing Network)--Apr 18, 2007 -- HealthSonix (Other OTC:HSXI.PK ) (Frankfurt:H7S.F ) announced today that it will commence with the sales of the new AquaSonix Therapy medical device to Hospitals, Rehabilitation Centers, and other professional medical facilities."Until now, the AquaSonix Therapy was only used in company owned and operated treatment centers, but the demand for the AquaSonix Therapy treatments dictated that we make product available to other professional healthcare facilities," said Dieter Doederlein, Vice President of Corporate Development for HealthSonix. "AquaSonix is a new treatment that combines the company's proprietary sound pulse technology with individualized low impact exercises in warm water therapy pools."
"To date, 4 out of five patients treated report a reduction in pain averaging 51%, significant improvement in physical function, and a reduction in stiffness," said Dr. David Venturi, Company's Medical Director. "The pain reduction results achieved by the AquaSonix Therapy are indeed consistent with the known positive effects of sound pulses when applied directly to the human body. Sound pulses work on the central nervous system by stimulating the mechanoreceptors located in the skin. The end effect is a reduction in pain and patients can progressively increase their exercise regimen in the pool. The resultant Relaxing effects also allow patients to sleep better."
The price of each AquaSonix Therapy device is $19,995 USD, which includes a complete training program for designated therapists, and access to the company's proprietary computerized patient management software system. In addition to the initial sales revenue the Company will see ongoing service revenues from the installed systems.
HealthSonix, Inc. (HSXI) is a publicly traded medical technology company. The Company's core offerings are based on proprietary, patent pending medical technologies that use sound pressure waves to administer sub-sensory micro vibration to the human body. Precisely formatted low frequency sound pressure waves are 80% effective in treating the chronic pain of many diseases, particularly arthritis. All treatments and products are safe, non-invasive and have no known side effects.
More information regarding HealthSonix and its products and services can be found at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Source: HealthSonix
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!